This study shows that type 2 diabetes causes decreased blood flow and changes in neural activity in specific parts of the hippocampus, which may initially compensate for cognitive decline but deteriorate with worsening diabetes. Highlights: Decreased Perfusion: Patients with type 2 diabetes have lower blood flow in the right hippocampal CA1, DG, and subiculum areas. …
GLP-1 receptor agonists like semaglutide, used for managing Type 2 diabetes, may be linked to adverse mood changes, necessitating further investigation into their psychiatric effects. Highlights: GLP-1 Receptor Agonists: These medications mimic GLP-1 hormone effects, enhancing insulin secretion and reducing appetite, commonly used for Type 2 diabetes management. Mood Effects: Data on the impact of …
TLDR: GLP-1 agonists were found to significantly reduce the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) compared to DPP-4 inhibitors and sulfonylureas. Highlights: A sequential trial emulation was conducted using data from Swedish national registers from 2010 to 2020, involving 88,381 participants aged 65 or older with T2DM. The incidence …
Semaglutide is emerging as a wonder drug for management of various metabolic diseases. Originally approved for type 2 diabetes, this glucagon like peptide-1 (GLP-1) receptor agonist is now showing promise for treating obesity, non-alcoholic steatohepatitis (NASH), and neurodegenerative diseases like Alzheimer’s and Parkinson’s. Let’s explore the therapeutic potential of semaglutide and how it acts as …
A new study looked at how having diabetes may impact brain health in Native Americans. The researchers found that the longer someone had diabetes, the more it affected their brain. But other health issues like obesity did not appear to impact the brain as much. Key facts: The study involved 51 Native Americans with type …
